American Society of Clinical Oncology Annual Meeting: Thyroid Cancer

Articles

Survivors of thyroid cancer had a higher risk of unemployment at 2 years post-diagnosis and decreased income at both 2 and 4 years, according to the results of a study.

Thyroid Cancer Diagnosis Affects Employment, Income

Use of transcriptional data taken from the FNA of thyroid nodules could help in predicting recurrence post surgery in certain thyroid cancer patients.

FNA Analysis Could Help Predict Thyroid Cancer Recurrence Risk

Two subgroup analyses of the SELECT trial could help clarify which differentiated thyroid carcinoma patients will benefit most from lenvatinib.

SELECT Subanalyses Provide Patient Selection Insight for Lenvatinib

First-line lenvatinib may improve progression-free survival in patients with 131I-refractory differentiated thyroid cancer with no prior history of VEGF therapy.

First-Line Lenvatinib May Improve PFS in Thyroid Cancer

Adding everolimus to sorafenib at the time of progression of advanced radio-iodine refractory differentiated thyroid carcinoma was tolerable and active.

Everolimus Active in Thyroid Cancer After Sorafenib Progression

Videos

In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.

EXAM: Cabozantinib Doubled Survival in Medullary Thyroid Carcinoma With RET M918T Mutation

Cabozantinib failed to significantly increase overall survival compared with placebo in patients with medullary thyroid carcinoma, according to the EXAM study.

Final Cabozantinib OS Results Fail to Show Improvement

Tumor growth rate analysis may be a valuable efficacy parameter to consider in patients with sorafenib-treated, radioiodine-refractory differentiated thyroid cancer.

American Society of Clinical Oncology Annual Meeting: Thyroid Cancer | Conference